Trial Profile
A Study to Evaluate the Impact of Minimal Residual Disease (MRD) Response on Overall Survival in Multiple Myeloma (MM) Patients Treated with Bortezomib-Thalidomide-Dexamethasone after Autologous Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics; Therapeutic Use
- 23 Dec 2015 New trial record